Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials. J of Skin [Internet]. 2023 Mar. 13 [cited 2025 May 17];7(2):s115. Available from: https://skin.dermsquared.com/skin/article/view/1966